Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction

Arnoud W.J. van ‘t Hof, C. Michael Gibson, S. A. O. F. Rikken, James L. Januzzi, C. B. Granger, A van Beurden, Saman Rasoul, Lex A. W. Ruiters, Jindra Vainer, Ashley Verburg, Fatih Arslan, J. Wouter Jukema, Marcel E. Durieux, Jawed Polad, Rick van der Vliet, Ben J L Van den Branden, Michael Magro, Wouter Remkes, Janne Beelen, Renicus S. Hermanides, Rudolf T Tolsma, M. Gosselink, Dragoş Vinereanu, Valentin Chioncel, Tim P. van de Hoef, René Boomars, Karin Arkenbout, Gert K. van Houwelingen, G. Hengstman, Henri van de Wetering, Ron Pisters, Petr Kala, Béla Merkely, Patrick Ecollan, Frédéric Lapostolle, Robert P. Giugliano, Robert C. Welsh, Miles Levy, Alexandra Arias‐Mendoza, N. Baron, Daniel Cociorva, Janet Wittes, Ellis F. Unger, Barry S. Coller, J. M. ten Berg, G Montalescot

In patients with STEMI, zalunfiban administered at first medical contact significantly improved preintervention infarct-related patency and reduced the likelihood of a worse 30-day multicomponent hierarchical clinical end point. Zalunfiban was not associated with increased severe or life-threatening bleeding but was associated with increased mild to moderate bleeding. (Funded by CeleCor Therapeutics; CELEBRATE ClinicalTrials.gov number, NCT04825743.).